Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
Authors
- L. Immisch
- G. Papafotiou
- O. Popp
- P. Mertins
- T. Blankenstein
- G. Willimsky
Journal
- Journal for ImmunoTherapy of Cancer
Citation
- J Immunother Cancer 11 (3): e006784